Mainz Biomed NV (MYNZ) News & EventsMYNZNews & EventsMainz Biomed NV

Mainz Biomed Renames to Quantum Cyber, Changes Ticker to QUCY

Mainz Biomed, doing business as Quantum Cyber, announced, effective upon the commencement of trading on March 12, it officially changed its ticker symbol to "QUCY" on the Nasdaq Capital Market. Further the Company's name will change to Quantum Cyber effective with a general meeting of shareholders planned for April 2026. The corporate name change and stock ticker symbol change reflect the Company's business strategy and better reflect the future operations, which will include a shift toward quantum computing and cybersecurity-oriented offerings.

Mainz Biomed Appoints Robert Liscouski as Chairman and Renames to Quantum Cyber

Mainz Biomed announced that Robert Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on March 12, 2026.

Mainz Biomed Signs $6M Financing Agreement

Mainz Biomed announced a series of strategic transactions designed to strengthen its liquidity position, transition the business to a focus on its pancreatic cancer detection program in the U.S., and provide flexibility as the Company continues its operations while evaluating growth opportunities and broader strategic alternatives. On February 13, 2026, Mainz Biomed entered into a securities purchase agreement for a $6M private placement with investor David Lazar. The financing will be completed in two tranches of $3M each through the issuance of Convertible Non-Redeemable Preferred Stock. The first $3M closing was completed on February 13, 2026. The second $3M n closing is expected to occur following receipt of required stockholder approvals and prior to April 15, 2026. Net proceeds from the private placement are expected to be used to fund ongoing operations, address outstanding liabilities, and preserve the Company's ability to operate while it pursues strategic initiatives. In conjunction with the financing the Company named David Lazar as Chairman of the Board of Directors. As the Company transitions its focus on developing its pancreatic cancer screening business in the U.S., it will continue to evaluate opportunities to sell its colorectal cancer screening assets while it also winds down its German subsidiary. The Company is currently in discussions with several parties interested in its colorectal cancer assets. This allows the Company to significantly reduce its operating expenses and extend its runway.